Lilly's chief executive calls Medicare coverage a potential 'game changer' for the pill launch

Eli Lilly CEO David Ricks told CNBC on Jan. 30 that upcoming Medicare coverage of obesity medicines could be a bigger factor in the launch of orforglipron, the company's experimental weight-loss pill, than the drug's price tag ^[1]. Ricks said Lilly expects Medicare coverage "immediately following" the pill's launch, calling that timing something that "will change the game a bit too" ^[1].

Ricks said Lilly is preparing for a "full launch" of orforglipron, sold under the brand name Foundayo, in the second quarter of 2026 ^[1]. That rollout is expected to coincide with Medicare covering obesity medicines for the first time, under drug pricing deals Lilly and Novo Nordisk struck with the Trump administration in November 2025 ^[1]. Under those deals, certain Medicare patients would pay a $50 monthly copay for all approved uses of injectable and oral GLP-1 drugs, covering both diabetes and obesity treatment ^[1].

Ricks estimated that 20 million to 30 million Medicare beneficiaries with obesity and related health conditions could become eligible for GLP-1 treatments once coverage begins, calling it a "big multiplier on the eligible pool" ^[1]. He pointed to the early performance of Novo Nordisk's Wegovy pill, which launched earlier in January, as a sign of demand even without broad insurance coverage; Ricks said he noticed that nearly all early adopters of that pill were new to GLP-1 treatments rather than switching from existing injections ^[1].

Ricks also acknowledged that the pricing deal will bring "a step down in pricing" for Lilly's drugs early in 2026, but said volume growth "will ramp on the back half of the year" as Medicare coverage takes effect ^[1]. He said Lilly views that as "a positive balance," though the outcome will depend on how many Medicare patients actually start treatment and how much of that market Lilly captures ^[1]. The company said it would give more detail on the financial impact of the pricing deal when it reports fourth-quarter earnings and 2026 guidance the following week ^[1].

The pricing agreements also include commitments to sell drugs at discounted cash-pay prices through a direct-to-consumer platform called TrumpRx, which was expected to launch in January but was not yet live as of the interview ^[1]. Ricks noted that Lilly's own direct-to-consumer platform, LillyDirect, was first to sell obesity treatments directly to patients, and said TrumpRx is "taking that and expanding it across the industry" to other medicines ^[1].

Why it matters for patients

Medicare has been barred by statute for two decades from covering obesity drugs, so this shift, if it proceeds as described, would open a large new group of older adults to potential coverage for GLP-1 pills and injections ^[1]. For patients currently paying cash, as many early Wegovy pill users reportedly are, a $50 monthly copay under Medicare could substantially lower out-of-pocket costs once coverage begins ^[1]. Some health experts cited by Lilly's CEO say broader Medicare coverage could also encourage more private insurers to expand their own coverage of these medicines ^[1]. However, the pricing deal also brings lower list prices for the drugs starting early in 2026, meaning the financial picture for both companies and patients could shift in ways that are not yet fully known ^[1].

What happens next

Lilly plans a full launch of orforglipron in the second quarter of 2026, timed closely with the start of Medicare coverage for obesity drugs ^[1]. The TrumpRx direct-to-consumer platform, part of the pricing deal, had not launched as of late January despite an original expected start date of January ^[1]. Lilly said it would share more financial detail tied to the pricing deal when it reports fourth-quarter 2025 earnings and 2026 guidance the following week ^[1].